Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum
Sponsor: London School of Hygiene and Tropical Medicine
Summary
Erythema Nodosum Leprosum (ENL) is a painful, debilitating complication of leprosy. Patients often require high doses of corticosteroids for prolonged periods. Thalidomide is expensive and not available in most countries. The use of corticosteroids for long periods is associated with adverse effects and mortality. It is a priority to identify alternative agents to treat ENL. Methotrexate (MTX) is a cheap, widely used medication which has been reported to be effective in ENL resistant to steroids and thalidomide.
Official title: Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
550
Start Date
2023-01-15
Completion Date
2025-10-01
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
Methotrexate
Participants in the intervention group will receive methotrexate along side prednisolone
Placebo
Participants in the control arm will receive placebo along side prednisolone
Prednisolone
Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
Locations (7)
TMLI Bangladesh/ DBLM hospital
Dhaka, Bangladesh
FIOCRUZ
Rio de Janeiro, Brazil
ALERT
Addis Ababa, Ethiopia
The Leprosy Mission Trust
Delhi, India
Bombay Leprosy Project
Mumbai, India
Soetomo Hospital
Surabaya, Indonesia
Anandaban Hospital
Kathmandu, Nepal